Genetics Testing

What’s Up With Illumina’s Acquisition of GRAIL?

If you want to land a job at a top investment bank, there’s an expectation that you’ve read certain material. Even though prop trading desks have gone the way of the dodo, books like Liar’s Poker and Reminiscences of a Stock Operator are must-reads. So is the 592-page monster, Barbarians at the Gate, a glimpse […]

Oxford Nanopore Stock: The Internet of Living Things

If you took all the stocks in the world and put them in a single basket, about 58% of that combined market cap would be U.S. stocks. If you want to look that number up, just download a fact sheet for the MSCI ACWI IMI Index. All those cryptic acronyms mean that the index includes […]

8 Whole Genome Sequencing Companies for Precision Health

Earlier this year, we picked apart the 23andMe stock offering for genetic testing. The financial picture looked stagnant, with 23andMe (ME) trying to build interest in the company’s FDA-authorized health insights and a subscription service that provides access to additional reports as they become available. As we noted in the article, the company’s most valuable […]

Is 23andMe Stock a Good Play on Genetics Testing?

With more than 9,700 hedge funds in operation around the planet, it’s highly unlikely that a handful of amateur stock manipulators on Reddit are bringing down Wall Street. It’s a myth that the media continues to perpetuate, further exacerbating the problem by encouraging even more dumb money to enter the fracas. What you are seeing […]

Calico Purring Right Along With Life Extension Research

Earlier this month, Alphabet (GOOG) took the air out of its Loon subsidiary, a former moonshot project for deploying internet around the world using high-flying balloons. Apparently, the economics just didn’t work out. No word on how much Google’s parent company spent on Loon, but SoftBank had sunk $125 million into the business in 2019. […]

Why is Illumina’s Stock Price Falling?

Fewer than half of Americans own a passport. Some say that’s because their own backyard is such a big one. The half of our audience that hails from there may not be aware of what’s happening with global travel because they’re blissfully watching the stock market soar inexplicably. According to the World Tourism Barometer, international […]

Invitae Stock – A Pure-Play on Genetics Testing

We research and write about tech companies and stocks religiously, but we’ve learned the hard way that trying to cherry-pick winning stocks is a high-risk game. No matter how promising the thesis, every company can potentially implode. In an attempt to weed out the land mines, we look for companies with strong industry partnerships (as […]

When Are Genetic Health Tests Worth Taking?

Investors in Illumina must be stoked about how things have been going so far for a company that commands a dominant market share in one of the most transformative technologies of our time – genetic sequencing. It’s allowed us to pursue promising technologies like gene editing – and now base editing – which means we can start […]

Centogene: Genetic Testing for Rare Diseases

You probably don’t know much about rare diseases unless you’re one of the unfortunate few who are afflicted by one. Not everyone agrees upon how we ought to define a rare disease, but in the United States, that’s considered one that affects less than 200,000 people or about 1 in 1,636 people. While some diseases […]

9 Genomics Startups for Investors to Watch

The history of direct-to-consumer genomics tests goes something like this. Genomics startups first started offering hereditary tests that required a DNA sample and everyone quickly climbed on board without realizing just how much information they were handing over to people they didn’t really know that well. Eventually, testing companies started moving into DNA health tests and then the FDA […]